Stimulator of interferon genes, or STING, agonists have enjoyed a bit of buzz over the past 10 years. Takeda, Eisai and other firms are evaluating the innate immune response stimulators in clinical trials in multiple cancer types including advanced solid tumors.

In light of the country’s expected growth as a medtech market, Siemens Healthineers has made the decision to split China out from the Asia-Pacific region at the corporate level, elevating it to its own seat at the company’s table.

In under a minute, an artificial intelligence program can take a picture of the back of a person’s eye and—by analyzing the strength of the blood vessels that feed the retina—find clues that may point to higher risks of a stroke or heart attack.

Amblyopia, or lazy eye, is often treated at a young age with the use of eye patches, worn over the stronger eye for several hours a day to help stimulate the eye with poorer vision.

Salvation may be on the horizon for Nektar Therapeutics, months after persistent clinical losses resulted in the end of its multi-billion-dollar deal with Bristol Myers Squibb and significant layoffs.

The allogeneic CAR-T cell therapy space is set for its biggest test yet. After ironing out the protocol with the FDA, Allogene Therapeutics has kicked off the first phase 2 clinical trial of an off-the-shelf candidate, setting it up to show how its CD19-directed prospect fares in a potentially pivotal study.

By keeping tabs on the data from Abbott’s wearable continuous glucose monitor, people with Type 1 diabetes were able to better control their blood sugar and reduce their HbA1c levels after six months, according to a randomized study.

After doubling down on its drug hunting partnership with BenevolentAI earlier this year, AstraZeneca is once again reaping the benefits.

Bristol Myers Squibb has high expectations for ConcertAI’s digital solution for clinical trials, suggesting it could become the “gold standard” for studying oncology therapies.

TauRx Pharmaceuticals is set to test the regulatory bar for approval of Alzheimer’s disease drugs in the post-Aduhelm world. The company was unable to show how its candidate performed compared to the control arm in a phase 3 clinical trial—but it plans to use the data set to seek approval anyway.